Document Type


Publication Date



This article has been peer reviewed. It is the authors' final version prior to publication in Current Opinion in Neurology, Volume 32, Issue 3, June 2019,Pages 405-412.

The published version is available at Copyright © Wolters Kluwer Health


PURPOSE OF REVIEW: Migraine is a common, highly disabling disorder. Its treatment involves acute and preventive therapy. Many of available preventive medications are not well tolerated, which results in poor compliance and limited effectiveness. Cannabinoids have been proposed for the treatment of migraine but their efficacy and tolerability are controversial.

RECENT FINDINGS: Cannabinoids modulate functions and activity of signaling pathways that have a key role in pain control. Growing preclinical evidence and initial clinical findings suggest that modulation of the endocannabinoid system, via endogenous or exogenous cannabinoids may be relevant for migraine via multiple mechanisms.

SUMMARY: The endocannabinoid system qualifies as an interesting area of research worth exploration in the quest for therapeutic targets for the treatment of migraine.

PubMed ID




Available for download on Monday, June 01, 2020

Included in

Neurology Commons